Astellas Pharma Inc. is seeking approval for eye treatment Izervay in Japan and Europe, a bid to expand sales to counter a potential revenue drop for its top cancer medicine.
Source link
Astellas Seeks Green Light for Eye Drug Izervay in Europe, Japan
Related Posts
Vista Winds Down Hedge Fund, Citing Dominance of Private Markets
Vista Equity Partners has told investors it’s winding down its hedge fund amid a “structural shift” in markets toward private assets. Source link
T-Mobile Postpones $561 Million Wireless Equipment ABS Offering
T-Mobile US Inc. is postponing its sale of more than $500 million in asset backed securities supported by wireless equipment plans, according to people familiar with the matter. Source link